Articles
7,608 Articles
Psychedelic Invest
/
Nov 20, 2024
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel has granted Psyence...
Psychedelic Invest
/
Nov 20, 2024
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held...
DoubleBlind Mag
/
Nov 19, 2024
Down the Rabbit Hole with “White Rabbit” Mushrooms
When we think of “White Rabbit,” many of us are likely to think of Alice In Wonderland and the white rabbit who rushes in from offscreen, “I’m late! I’m late! For a very important date! No time to say hello, goodbye!” then disappears down a rabbit hole. Led by Alice, who out of curiosity...
Psilocybin
Psychedelic Invest
/
Nov 19, 2024
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second...
Psilocybin
Psilocybin Alpha
/
Nov 19, 2024
Psychedelic Investor Survey Q3 2024
Topline results from the latest in our series of psychedelics investor surveys. ∎ In late Q3’24, we distributed our Psychedelics Investor Survey. Prior to that, our last survey was back in Q4 2022, making this latest instalment long overdue.Indeed, lots has changed in that nearly two-year...
Psychedelics
Psychedelic Invest
/
Nov 19, 2024
Braxia Scientific Announces Change in Directors and CEO
Toronto, Ontario–(Newsfile Corp. – November 18, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”) announced that Jerry Habuda has resigned as a director effective November 12, 2024. Peter Rizakos was appointed on the same date by the...
Psychedelics Today
/
Nov 19, 2024
Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry
While the psychedelic industry is facing intense growing pains, the ketamine industry has been allowed to grow, largely unchecked. How did we get here, and how does the ketamine space rebuild trust? In this episode, Kyle interviews Juan Pablo Cappello: co-founder and former CEO of Nue Life Health,...
Ketamine
DoubleBlind Mag
/
Nov 18, 2024
The Psilocybin Mushroom Market Is Expected To Reach $3.3 Billion by 2031
The psychedelic mushrooms market is headed for a billion-dollar payday, according to a new market forecast report. The Persistence Market Research report projects the global psychedelic mushrooms market will reach $3.3 billion by 2031. For comparison, the all-terrain vehicle or ATV market is...
Psilocybin
MDMA
Psychedelic Invest
/
Nov 18, 2024
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief...
Microdose
/
Nov 18, 2024
Introduction to Jill Sitnick: A Courageous Journey from Healing to Advocacy
When I first spoke with Jill Sitnick, founder of Journey Sage LLC, I was struck by her candidness and determination to share a story that is both deeply personal and profoundly important. Jill’s journey from grappling with debilitating PTSD to becoming a passionate advocate for MDMA-assisted...
Psilocybin
MDMA
Psychedelic Invest
/
Nov 18, 2024
PharmaDrug Announces Issuance of Debenture Units
Toronto, Ontario–(Newsfile Corp. – November 15, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines and...
Psychedelic Invest
/
Nov 18, 2024
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO, November 18, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options,...
Psychedelic Invest
/
Nov 18, 2024
Numinus Applies for Management Cease Trade Order
VANCOUVER, BC, Nov. 15, 2024 /PRNewswire/ – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company“), a leader in mental health care specializing in innovative and evidence-based treatments, announces that it has requested a temporary Management Cease Trade Order...
DoubleBlind Mag
/
Nov 18, 2024
Mushroom Gummies 101: Here’s Everything You Need to Know
So you want to buy mushroom gummies but don’t know where to start? You’re in luck! We wrote this to help guide you from the mystical to the practical, offering insight for the most informed choice — plus, we include a recipe to boot. What Are Mushroom Gummies? Mushroom gummies are the chewy...
Psilocybin
Ayahuasca
Psychedelic Invest
/
Nov 18, 2024
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
Psychedelics - Green Market Report
/
Nov 15, 2024
Filament Health revenue slides 94% as cash reserves dwindle
Vancouver-based Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) saw its cash reserves continue to decline as third-quarter revenue plummeted to $19,021, from $337,470 in the same period last year, according to financial results Thursday. The clinical-stage psychedelic drug development firm ended...
Zen Habits
/
Nov 15, 2024
Thoughts on Healthy Eating
By Leo Babauta Eating healthy is something I’ve been a bit obsessed with for the last couple of decades, and I’ve transformed my eating in some really fundamental ways: I eat way less junk food than beforeI have developed a real love for whole, nutritious foodsI’m vegan (for ethical reasons)I...
Psilocybin Alpha
/
Nov 15, 2024
Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding
Last-minute donations from Dr. Bronner’s ($100k), Elliot Cohen ($100k), Eliza Dushku ($100k), MAPS ($50k), and others could not push Question 4 over the line, with the Massachusetts ballot initiative suffering defeat by a convincing margin. (See Question 4 Fails: Massachusetts Says No to...
Psychedelics
Psychedelics - Green Market Report
/
Nov 15, 2024
Numinus to sell five Utah ketamine clinics to Stella for $3.5M in tech pivot
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) agreed to sell its five Utah clinics to psychiatric care provider Stella. The deal will also create a data-sharing partnership to develop clinic management software, as the struggling psychedelics company moves away from direct patient care. The...
LSD
MDMA
Psychedelic Invest
/
Nov 15, 2024
Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
VANCOUVER, BC, Nov. 15, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted...
Psychedelic Invest
/
Nov 15, 2024
Filament Health Announces Third Quarter 2024 Financial Results and Operational Highlights
VANCOUVER, BC, Nov. 14, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period...
Psychedelics Today
/
Nov 15, 2024
From Individualism to Connection: How Psychedelics and Group Therapy Can Heal Our Collective Crisis
It becomes more apparent every day how much isolation and focusing so much on the individual is hurting us. Can psychedelics – and specifically, group therapy – be the answer to our crisis of individualism? In this episode, Kyle interviews Geoff Bathje, Ph.D.: licensed psychologist, researcher,...
Psychedelics
Psychedelics - Green Market Report
/
Nov 15, 2024
Enveric Biosciences narrows net loss, advances lead drug candidate
Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the third quarter of 2024 and provided a corporate update yesterday. Enveric said it made “important progress” in the development of EB-003, its lead neuroplastogenic molecule designed to treat depression, anxiety and...
DMT
DoubleBlind Mag
/
Nov 14, 2024
The VA Is Funding A Study to Determine If MDMA Can Really Treat PTSD
The Department of Veterans Affairs (VA) is taking a leading role in the new fight to approve MDMA-assisted therapy for PTSD after the Food and Drugs Administration refused to green-light the treatment earlier this year, raising issues and requesting new data. The VA is well aware of the urgent need...
MDMA
DoubleBlind Mag
/
Nov 14, 2024
Top 6 Trippiest Movies You Can Stream on Netflix
Forget the rabbit hole. Dive headfirst into a dead star’s vortex with our curated list of trippy movies on Netflix. These cinematic gems will warp your perception with twisted narratives, mind-melting visuals, and cacophonous soundtracks that will leave you questioning reality. From dream-laden...
LSD
Psychedelic Invest
/
Nov 14, 2024
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has...
MDMA
Psychedelics - Green Market Report
/
Nov 14, 2024
Cybin posts second-quarter loss widens as clinical trials advance
Toronto-based Cybin Inc. (NYSE: CYBN) reported financials for its fiscal second quarter 2025 ending Sept. 30, with higher R&D costs from its clinical programs. The company also announced it has initiated a phase 3 program evaluating its psilocin-based CYB003 for the adjunctive treatment of...
Psychedelic Invest
/
Nov 14, 2024
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a...
Psychedelics - Green Market Report
/
Nov 14, 2024
GH Research reports deeper losses as DMT clinical trial costs mount
Dublin-based GH Research PLC (Nasdaq: GHRS) reported a deeper quarterly loss and climbing R&D expenses as it continues to run its clinical trials, but it still maintains a strong cash position to support its efforts. The clinical-stage psychedelic medicine maker, which is trying to develop...
DMT
Microdose
/
Nov 13, 2024
Enveric and MycoMedica’s New Licensing Agreement Marks a Strategic Shift in Mental Health Treatment
In a move that underscores both innovation and adaptation in the mental health treatment landscape, Enveric Biosciences recently announced a licensing agreement with MycoMedica Life Sciences, paving the way for a new chapter in psilocin-based drug development. Through this agreement, MycoMedica...
Psychedelic Invest
/
Nov 13, 2024
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM,...
DMT
Psychedelic Invest
/
Nov 13, 2024
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
NEW YORK and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced third...
DMT
Psychedelics - Green Market Report
/
Nov 13, 2024
Atai posts $26M loss, but progresses on psychedelic clinical trials
New York-based Atai Life Sciences (Nasdaq: ATAI) reported a net loss of $26.3 million for the third quarter, down year-over-year from its net income of $43.3 million, but the clinical-stage biopharmaceutical company also noted it’s well-positioned to bring multiple mental health drugs to market...
DMT
DoubleBlind Mag
/
Nov 13, 2024
Explore the Depths of Your Psyche with Trippy, Dark Psychedelic Art
Psychedelics can take you to many places and evoke many states: mirth, joy, awe, fascination, and sometimes… sadness. Psychedelic art accordingly covers the vast array of human emotions, both the light and the dark. Often, sad, dark psychedelic art evokes feelings that make you reflect, helping...
LSD
Psychedelics
Psychedelic Invest
/
Nov 13, 2024
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq Form 6 K
NEW YORK, November 12, 2024 — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on November 12, 2024 (the “Meeting”)....
DoubleBlind Mag
/
Nov 13, 2024
Electronic Music Pioneer Don Slepian Is Playing a Live Musical Ketamine Journey
On Thursday, November 14th, legendary electronic musician Don Slepian will perform at a supervised ketamine journey in Los Angeles — a groundbreaking event that could pave the future of music-assisted psychedelic therapy. The experience was organized by The MCPI Group, and will be their first in a...
Ketamine